胎肝细胞输注对癌症病人化疗中外周血白细胞变化干预的序贯试验研究  

The Medical Sequential Trial of Foetus Liver Cells Transfusion Disturbing White Blood Cells Reduction Caused by Chemotherapy

作　　者：李苏宜[1] 吴孔明[1] 周云[1] 王丽萍[1] 

机构地区：[1]河南医科大学一附院肿瘤科

出　　处：《河南肿瘤学杂志》1994年第1期20-23,共4页Henan Journal of Oncology

摘　　要：本文自１９９１年１月以来．进行了静脉输注胎肝细胞悬液干扰化疗药物降白副反应的医学序贯试验。实验组病人静脉输注４～６月胎龄胎肝细胞悬液１６００～４０００ｍｌ（浓度５～７×１０９个／Ｌ），对照组按常规方法升白。通过２８例病人的序贯试验发现化疗期间输注胎肝细胞悬液的病人骨髓抑制发生延迟，持续时间短，程度减轻，从而为化疗正常进行提供基本条件。结论；胎肝细胞悬液输注可干扰化疗药物降白副反应的发生。A medical sequential trial has been tested since Jan, 1991 to study tthe effect of foetus liver cells (FLC) transfuion on disturbing paripheral vascular white blood cell(WBC) reduction caused by chemotherapy. 28 patients were selected from FLC transfusion group or control group in random and matched 1: 1 pair in the same cancer and sex. The patients of FLC group were transfused 8-28×1012 cells during 21 days. Both of the matched patientpair were examined WBC in the same way. The result of medical sequential order test was that the peripheral vascular WBC of the patients in FLC group reduced with delay and rose again quickly [false positive (α) was 0. 1 and false negative (β) was 0. 05]. And another result was got from a medical seqentical test (α=β=0.01).Myelosuppresion was markedly slight in FLC group. It is effective for the patients with carcinoma during chemotherapy to be transfused FLC to disturb myelosuppresion caused by chemotherapy.

关 键 词：医学序贯试验 肿瘤 药物疗法 胎肝 

分 类 号：R730.53[医药卫生—肿瘤]